Diazepam treatment of early signs of exacerbation in schizophrenia

William T. Carpenter, Robert W. Buchanan, Brian Kirkpatrick, Alan Breier

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Objective: Therapeutic intervention at the earliest phase of symptom exacerbation in schizophrenia is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illness have not been established. This study examined diazepam efficacy for this phase of treatment. Method: A double-blind, randomized clinical trial with 53 schizophrenic patients compared diazepam with placebo (with fluphenazine treatment for a comparison group). Treatment was initiated at the earliest signs of exacerbation, and symptom progression was the dependent measure used to evaluate efficacy. Results: Diazepam was statistically superior to placebo in preventing symptom progression and was comparable to fluphenazine. Conclusions: Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia. This therapeutic strategy may be especially important for patients who refuse antipsychotic drugs or as a supplemental approach in a treatment plan that emphasizes low-dose antipsychotic therapy.

Original languageEnglish (US)
Pages (from-to)299-303
Number of pages5
JournalAmerican Journal of Psychiatry
Volume156
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Diazepam
Schizophrenia
Fluphenazine
Antipsychotic Agents
Signs and Symptoms
Therapeutics
Placebos
Double-Blind Method
Randomized Controlled Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Carpenter, W. T., Buchanan, R. W., Kirkpatrick, B., & Breier, A. (1999). Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry, 156(2), 299-303.

Diazepam treatment of early signs of exacerbation in schizophrenia. / Carpenter, William T.; Buchanan, Robert W.; Kirkpatrick, Brian; Breier, Alan.

In: American Journal of Psychiatry, Vol. 156, No. 2, 02.1999, p. 299-303.

Research output: Contribution to journalArticle

Carpenter, WT, Buchanan, RW, Kirkpatrick, B & Breier, A 1999, 'Diazepam treatment of early signs of exacerbation in schizophrenia', American Journal of Psychiatry, vol. 156, no. 2, pp. 299-303.
Carpenter, William T. ; Buchanan, Robert W. ; Kirkpatrick, Brian ; Breier, Alan. / Diazepam treatment of early signs of exacerbation in schizophrenia. In: American Journal of Psychiatry. 1999 ; Vol. 156, No. 2. pp. 299-303.
@article{bf6d01a6d75544b982a8d170309179e4,
title = "Diazepam treatment of early signs of exacerbation in schizophrenia",
abstract = "Objective: Therapeutic intervention at the earliest phase of symptom exacerbation in schizophrenia is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illness have not been established. This study examined diazepam efficacy for this phase of treatment. Method: A double-blind, randomized clinical trial with 53 schizophrenic patients compared diazepam with placebo (with fluphenazine treatment for a comparison group). Treatment was initiated at the earliest signs of exacerbation, and symptom progression was the dependent measure used to evaluate efficacy. Results: Diazepam was statistically superior to placebo in preventing symptom progression and was comparable to fluphenazine. Conclusions: Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia. This therapeutic strategy may be especially important for patients who refuse antipsychotic drugs or as a supplemental approach in a treatment plan that emphasizes low-dose antipsychotic therapy.",
author = "Carpenter, {William T.} and Buchanan, {Robert W.} and Brian Kirkpatrick and Alan Breier",
year = "1999",
month = "2",
language = "English (US)",
volume = "156",
pages = "299--303",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Diazepam treatment of early signs of exacerbation in schizophrenia

AU - Carpenter, William T.

AU - Buchanan, Robert W.

AU - Kirkpatrick, Brian

AU - Breier, Alan

PY - 1999/2

Y1 - 1999/2

N2 - Objective: Therapeutic intervention at the earliest phase of symptom exacerbation in schizophrenia is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illness have not been established. This study examined diazepam efficacy for this phase of treatment. Method: A double-blind, randomized clinical trial with 53 schizophrenic patients compared diazepam with placebo (with fluphenazine treatment for a comparison group). Treatment was initiated at the earliest signs of exacerbation, and symptom progression was the dependent measure used to evaluate efficacy. Results: Diazepam was statistically superior to placebo in preventing symptom progression and was comparable to fluphenazine. Conclusions: Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia. This therapeutic strategy may be especially important for patients who refuse antipsychotic drugs or as a supplemental approach in a treatment plan that emphasizes low-dose antipsychotic therapy.

AB - Objective: Therapeutic intervention at the earliest phase of symptom exacerbation in schizophrenia is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illness have not been established. This study examined diazepam efficacy for this phase of treatment. Method: A double-blind, randomized clinical trial with 53 schizophrenic patients compared diazepam with placebo (with fluphenazine treatment for a comparison group). Treatment was initiated at the earliest signs of exacerbation, and symptom progression was the dependent measure used to evaluate efficacy. Results: Diazepam was statistically superior to placebo in preventing symptom progression and was comparable to fluphenazine. Conclusions: Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia. This therapeutic strategy may be especially important for patients who refuse antipsychotic drugs or as a supplemental approach in a treatment plan that emphasizes low-dose antipsychotic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0344527721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344527721&partnerID=8YFLogxK

M3 - Article

C2 - 9989567

AN - SCOPUS:0344527721

VL - 156

SP - 299

EP - 303

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -